Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06698250
Title Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) (ZENOBIA)
Acronym ZENOBIA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Anwaar Saeed
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.